Crispr Therapeutics AG (CRSP) — Cash Flow Reinvestment Rate
Crispr Therapeutics AG (CRSP) has a Cash Flow Reinvestment Rate of 0.90x as of March 2024, reinvesting $98.52 Million (capex $721.00K plus investments $-97.80 Million) from operating cash flow of $109.75 Million. Explore Crispr Therapeutics AG (CRSP) reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Crispr Therapeutics AG Cash Flow Reinvestment Rate (2015–2021)
Historical reinvestment intensity for Crispr Therapeutics AG across 3 annual periods. Also explore Crispr Therapeutics AG assets under control for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Crispr Therapeutics AG (2015–2021)
Year-by-year capital reinvestment analysis for Crispr Therapeutics AG. For live market cap and broader valuation context, see how much is Crispr Therapeutics AG worth.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2021 | 1.92x | $1.04 Billion | $538.97 Million | $81.70 Million | ▲ +1259.5% |
| 2019 | 0.14x | $8.01 Million | $56.68 Million | $6.68 Million | ▲ +569.7% |
| 2015 | 0.02x | $1.25 Million | $59.43 Million | $1.15 Million | — |